Last month, drug company Genentech reported on the first clinical trials of the drug crenezumab, a drug targeting amyloid proteins that form sticky plaques in the brains of Alzheimer’s disease patients.
Two decades of Alzheimer’s research may be based on deliberate fraud
Written by Mark Sumner